CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpertother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04955717
NCT04955717N/ACompleted
CompareCT.gov

The Diagnosis and Treatment of Chlamydia Trachomatis and Neisseria Gonorrhoeae in Pregnant Women to Prevent Adverse Neonatal Consequences.

University of Southern California·interventional·Posted Jul 9, 2021·Updated Feb 3, 2025

In Brief

A clinical study evaluating Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert for Chlamydia Trachomatis Infection and 3 related conditions. Completed, enrolled 500 participants across 2 sites in 2 countries.

Detailed Summary

To assess the effectiveness of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing and treatment during pregnancy to reduce adverse pregnancy and birth outcomes compared to the standard of care (treatment based on symptoms and signs).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChlamydia Trachomatis Infection, Neonatal Infection, Preterm Birth, Gonorrhea
CountriesBotswana, United States
CollaboratorsBotswana Harvard AIDS Institute Partnership, University of California, San Diego

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 9, 2021
Enrollment StartFeb 24, 2021
Primary CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 5.0 years ago

Interventions

Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpertother

Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert